Piper Sandler Maintains Overweight on Milestone Pharmaceuticals, Lowers Price Target to $3

Benzinga · 3d ago
Piper Sandler analyst Edward Tenthoff maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight and lowers the price target from $7 to $3.